Inflammatory and procoagulant responses are often protective and yet may contribute to maladies such as sepsis and heart attacks. This study focuses on elucidating the role(s) of two carboxypeptidases (CP) in regulating the fibrinolytic and inflammatory responses. The two CP, activated TAFI (TAFla) and carboxypeptidase N (CPN) both remove C-terminal lysine and arginine residues from protein substrates. However, while TAFla prefers Arg, CPN prefers Lys substrates. Also, TAFI requires activation and may play a role in """"""""on demand"""""""" situations whereas CPN is constitutively active and may play a """"""""house-keeping"""""""" role. TAFla inhibits fibrinolysis and could exacerbate thrombosis whereas CPN may not. In contrast CPN is considered to play a predominant role in regulating inflammation by inactivating anaphylatoxins generated by complement activation whereas the role of TAFI in this process is unknown. How are these two enzymes independently regulated and how does the presence of one affect the total or overall activity? We believe that regulation of fibrinolysis and inflammation are mediated to different extents by TAFla and CPN but are not mutually exclusive. They act synergistically in order to maintain exquisite control of both hemostatic and inflammatory responses.
Our specific aims are to; 1) determine the correlation between functional and antigenic concentrations of TAFI in human plasma, 2) to assess the antifibrinolytic effects of TAFla and CPN in a purified system, 3) to determine the role of glycosaminoglycans on cell surfaces to participate in plasmin-mediated TAFI activation, 4) to determine the effect of CPN and TAFla on inhibition of C3a-mediated calcium ion efflux. Activity assays will be performed in a 2 x 2 matrix varying both concentrations of TAFla and CPN in order to assess synergistic effects. In the long-term this understanding this will lead to new therapeutic interventions which may specifically and significantly affect thrombosis without negatively affecting inflammatory responses or vice versa.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL078658-04
Application #
7274732
Study Section
Special Emphasis Panel (ZHL1-CSR-I (S1))
Program Officer
Kindzelski, Andrei L
Project Start
2004-09-30
Project End
2008-08-31
Budget Start
2007-09-01
Budget End
2008-08-31
Support Year
4
Fiscal Year
2007
Total Cost
$64,465
Indirect Cost
Name
University of Alberta
Department
Type
DUNS #
208095844
City
Edmonton
State
AB
Country
Canada
Zip Code
T6 2-E1
Bauman, Mary E; Black, Karina L; Massicotte, Mary P et al. (2008) Accuracy of the CoaguChek XS for point-of-care international normalized ratio (INR) measurement in children requiring warfarin. Thromb Haemost 99:1097-103
Walker, J B; Binette, T M; Mackova, M et al. (2008) Proteolytic cleavage of carboxypeptidase N markedly increases its antifibrinolytic activity. J Thromb Haemost 6:848-55
Binette, Tanya M; Taylor Jr, Fletcher B; Peer, Glenn et al. (2007) Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon. Blood 110:3168-75
Walker, J B; Bajzar, L (2007) Complete inhibition of fibrinolysis by sustained carboxypeptidase B activity: the role and requirement of plasmin inhibitors. J Thromb Haemost 5:1257-64